Bavarian Nordic
Clinical trials sponsored by Bavarian Nordic, explained in plain language.
Danish biotech company specializing in vaccines for infectious diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Mpox vaccine gets a production upgrade: new cell recipe under trial Results expected Nov 2026 (estimated)
- New vaccine aims to stop rare but deadly brain infections from mosquitoes Results expected Feb 2027 (estimated)
-
Chikungunya Vaccine's Long-Term shield put to the test
Vaccine OngoingThis phase 3 study follows healthy adults and adolescents who previously received a chikungunya vaccine in an earlier trial. It aims to see how long the vaccine's protection lasts and whether a booster shot can strengthen immunity years later. Participants will be monitored for u…
Phase 3 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Aug 09, 2026 00:00 UTC
-
Mpox vaccine gets a production upgrade: new cell recipe under trial
Vaccine OngoingThis study tests whether the MVA-BN mpox vaccine (Jynneos) works as well when made in quail cells instead of chicken cells. About 970 healthy adults aged 18 to 49 will receive two doses four weeks apart. Researchers will compare immune responses and side effects between the two v…
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 12:05 UTC
-
Mpox vaccine trial expands to children: a step toward broader protection
Vaccine OngoingThis study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in…
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 07:59 UTC
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
Vaccine OngoingThis Phase 2 trial tests a new vaccine called MVA-BN-WEV to prevent two types of equine encephalitis (Eastern and Venezuelan), which are rare but serious brain infections spread by mosquitoes. The study involves 411 healthy adults aged 18-50 and aims to find the best dose and dos…
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 07:52 UTC